Monopar Therapeutics
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
MNPR | NDAQ
Overview
Corporate Details
- ISIN(s):
- US61023L2079
- LEI:
- Country:
- United States of America
- Address:
- 1000 SKOKIE BLVD SUITE 350, 60091 WILMETTE
- Website:
- https://www.monopartx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Monopar Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for oncology and rare diseases. Its primary oncology program develops personalized radiopharmaceuticals to diagnose and treat advanced solid tumors, with a pipeline that includes clinical-stage imaging agent MNPR-101-Zr and therapeutic candidates MNPR-101-Lu and MNPR-101-Ac. In the rare disease space, the company is advancing ALXN1840, a late-stage investigational treatment for Wilson Disease. Monopar builds its pipeline through a combination of in-house efforts and the in-licensing of late-stage clinical assets, leveraging its management's expertise to accelerate development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Monopar Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Monopar Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Monopar Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
